The scientists at BSRC “Alexander Fleming” perform cutting-edge research, aiming to understand molecular mechanisms of complex biological processes in health and disease. We are also committed to contribute to innovation in medicine, by developing novel therapeutic and diagnostic methods, focusing on immunity and inflammation, cancer, and neurodegenerative diseases. To keep our focus on top-notch research, we recruit at all levels with excellence as the sole criterion and we support our researchers by providing state-of-the science infrastructures and a pleasant working environment. FLEMING is a non-profit organization operating under the auspices of the Greek General Secretariat for Research & Technology and is supported by the Greek government and by national, European and international grants.
Highlights
Fleming researchers have identified two new dual inhibitors of TNF and RANKL, two key factors involved in inflammatory processes. These inhibitors can be further optimized to develop improved treatments for a range of inflammatory, autoimmune, and bone loss diseases (PubMed, Ηighlights in international press).
Work by Fleming researchers has revealed that omic profiles of synovial fibroblasts from the Tg197 human TNF-transgenic model of arthritis greatly mimic human synovial fibroblast profiles from Rheumatoid arthritis patients, revealing commonly represented pathways that may constitute potential targets for future therapies (Pubmed, Editorial)
Following a Forward Genetics approach, Fleming researchers identified a novel neurological mouse model caused by a functional mutation in the Slc25a46 gene, a new pathogenic target in a wide spectrum of human neurological diseases, including optic atrophy, Charcot-Marie-Tooth type 2, Leigh syndrome, progressive myoclonic ataxia and lethal congenital pontocerebellar hypoplasia. Pubmed
Expanding previous work on the role of autotaxin in chronic inflammatory disorders that have led to phase II clinical trials in idiopathic pulmonary fibrosis, Fleming researchers have now uncovered a novel, major role for this secreted lysophospholipase D in the pathogenesis of hepatitis and hepatocellular carcinoma. PubMed.
NEWS AND EVENTS
19/05/2017
Seminar 19/05/2017, 12:30."Irreversible Inhibitors: Reinvention of a Very Old Paradigm", Peter Machin, PhD, Former Global Senior VP of Discovery Research Chemistry at GlaxoSmithKline, Board Member of Institute for New Medicine Discovery.
17/05/2017
Seminar 17/05/2017, 11:30. "30min to ask the Nobelist", Prof. Jules Hoffmann, 2011 Nobel Laureate in Physiology or Medicine, CNRS, University of Strasbourg.
PUBLICATIONS
Visit BSRC Fleming's scientific Publications web page
